Cancer Screening Test Articles & Analysis: Older

1 articles found

Nanostics Announces Study Data Supporting ClarityDX Prostate as a Reflex Test to Predict Clinically Significant Prostate Cancer

Real-world data shows that at a 94% sensitivity level for prostate cancer ClarityDX Prostate® is 147% more specific than the PSA test for predicting clinically significant prostate cancer. ...

Jul. 30, 2022

ByNanostics Inc.

Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you